OCULAR THERAPEUTIX INC's ticker is OCUL and the CUSIP is 67576A100. A total of 150 filers reported holding OCULAR THERAPEUTIX INC in Q2 2021. The put-call ratio across all filers is 0.38 and the average weighting 0.9%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $92,261 | -51.0% | 17,880 | -50.0% | 0.00% | -50.0% |
Q1 2023 | $188,455 | +87.5% | 35,760 | 0.0% | 0.00% | +100.0% |
Q4 2022 | $100,486 | -49.0% | 35,760 | -24.5% | 0.00% | -60.0% |
Q3 2022 | $197,000 | -78.4% | 47,381 | -48.0% | 0.01% | -80.0% |
Q3 2021 | $912,000 | -50.2% | 91,166 | -29.5% | 0.02% | -57.6% |
Q2 2021 | $1,832,000 | +164.7% | 129,225 | +206.4% | 0.06% | +126.9% |
Q1 2021 | $692,000 | -51.4% | 42,177 | -38.7% | 0.03% | -50.9% |
Q4 2020 | $1,425,000 | +9.0% | 68,846 | -59.9% | 0.05% | -32.9% |
Q3 2020 | $1,307,000 | -37.4% | 171,735 | -31.5% | 0.08% | -44.8% |
Q2 2020 | $2,088,000 | +127.0% | 250,712 | +34.8% | 0.14% | +88.2% |
Q1 2020 | $920,000 | +161.4% | 185,949 | +108.8% | 0.08% | +145.2% |
Q4 2019 | $352,000 | +28.0% | 89,077 | -1.6% | 0.03% | +24.0% |
Q3 2019 | $275,000 | +276.7% | 90,527 | +446.6% | 0.02% | +257.1% |
Q2 2019 | $73,000 | -85.5% | 16,561 | -69.4% | 0.01% | -93.3% |
Q2 2017 | $502,000 | – | 54,200 | – | 0.10% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
SUMMER ROAD LLC | 5,618,861 | $116,310,000 | 100.00% |
Opaleye Management Inc. | 6,510,000 | $134,758,000 | 17.60% |
DELTEC ASSET MANAGEMENT LLC | 2,168,573 | $44,889,000 | 6.87% |
Versant Venture Management, LLC | 1,465,384 | $30,333,000 | 3.15% |
GREAT POINT PARTNERS LLC | 856,162 | $17,723,000 | 2.88% |
Affinity Asset Advisors, LLC | 220,000 | $4,554,000 | 2.41% |
Altium Capital Management LP | 303,174 | $6,276,000 | 2.34% |
Endurant Capital Management LP | 290,465 | $6,013,000 | 2.17% |
MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 50,396 | $1,043,000 | 1.17% |
Lisanti Capital Growth, LLC | 366,040 | $7,577,000 | 1.05% |